Looking at the charts of the Psychedelics sector, they can best be described as a mixed bag. Just like Cannabis, shroom stocks are taking a hit. This could just…
mushrooms
You’d be hard pressed to find someone who hasn’t been touched by depression or anxiety. Biochemically, they’re considered co-morbid, which means they often happen at the same time and…
Week in Review (Week 7) From a blazing 30°C earlier this summer to a crisp 13°C today, there’s no denying that it’s cooling down outside. I have already started…
Filament Health (FH.NE) shipped their first batch of good manufacturing practices (GMP) certified natural psilocybin into the United States earlier this week, according to a press release. The…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Filament Health (FH.NE) received the first ever psilocybin (and other associated psychoactive compounds) extraction and standardization patent for a public company by the Canadian Intellectual Property Office today, according…
Cybin (CYBN.NE) announced today that it has closed its previously announced overnight marketed offering including the exercise in full of the over-allotment option granted to the Underwriters. “Investor demand…
PsyBio Therapeutics (PSYB.V) announced it has filed a new provisional patent application with the US Patent and Trademark Office. The new patent is entitled Psilocybin and Norbaeocystin Compositions and…
Cybin (CYBN.NE) announced today that it has completed its 51st pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (IND)-enabling studies. “These experiments…